Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
ResMed Inc. (RMD)
USD198.50
-5.37 (-2.63%)
US NYSE S&P 500
Healthcare Medical - Devices
Address
9001 Spectrum Center Boulevard 92123
San Diego, CA, US
San Diego, CA, US
CEO
Michael J. Farrell
Website
resmed.com
IPO
1995-06-02
CIK 943819 ISIN US7611521078
Also trades on
Australian Securities Exchange · RMD.AX (AUD)
London Stock Exchange · 0KW4.L (USD)
New York Stock Exchange · RMD (USD)
Other OTC · RSMDF (USD)
Description
ResMed Inc. is a leading global medical technology enterprise engaged in the creation, production, distribution, and marketing of healthcare devices and connected digital solutions. The company operates through two primary segments: Sleep and Respiratory Care, and Software as a Service. Its extensive product range addresses a variety of respiratory disorders, encompassing advanced medical and consumer technologies, ventilation devices, diagnostic equipment, mask systems for both clinical and personal use, headgear, and related accessories, alongside dental devices. ResMed also provides sophisticated cloud-based informatics to enhance patient management and operational efficiency. Notable software offerings in its respiratory portfolio include AirView, for remote device monitoring and setting adjustments; myAir, a personalized application designed to support sleep apnea patients with education and troubleshooting for better engagement and adherence; and U-Sleep, a compliance tracking platform for home medical equipment providers. Complementing these are connectivity modules and Propeller solutions. Furthermore, ResMed offers a robust suite of out-of-hospital software. This includes Brightree, a business management platform for various home care service providers (e.g., HME, pharmacy, infusion, orthotics, prosthetics); MatrixCare, providing care management for senior living, skilled nursing, and hospice organizations; and HEALTHCAREfirst, which supplies electronic health records, billing, coding services, and analytics for home health and hospice agencies. ResMed distributes its offerings primarily to sleep clinics, home healthcare dealers, and hospitals via a global network of distributors and a direct sales force, serving approximately 140 countries. Founded in 1989, the company's headquarters are located in San Diego, California.
News Sentiment (7d)
3 articles
- These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar Zacks Investment Research
- ResMed Analyst Backs Portfolio Reset Benzinga
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Index membership
| Index | Added | Removed | Status |
|---|---|---|---|
| S&P 500 | 2017-07-25 | — | Active |
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD198.50
-5.37 (-2.63%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
1M
Beta
0.78
Float Shares
144.39M
Free Float %
99.1%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +2.53% | -1.45% | -11.50% | -19.31% | -19.17% | -15.39% | -17.71% | -12.34% | +4.58% | +254.79% | +30,231.31% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (35 ratings, all time)
Buy
Price Targets & DCF
Current price
198.50
Low
225.00
+13.4%
Consensus
281.29
+41.7%
Median
275.00
+38.5%
High
345.00
+73.8%
DCF (Unlevered)
301.14
+51.7%
DCF (Levered)
501.97
+152.9%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
56% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 3 | 0 |
| Buy | 7 | -1 |
| Hold | 7 | 0 |
| Sell | 1 | 0 |
| Strong Sell | 0 | 0 |
Price Target Summary
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | 3 |
256.67
+29.3%
|
| Last Quarter | 3 |
256.67
+29.3%
|
| Last Year | 17 |
285.94
+44.1%
|
| All Time | 34 |
261.15
+31.6%
|
Quality scores
Altman Z-Score
10.48
Safe zone
Piotroski F-Score
7 / 9
Strong
MOAT Score
8 / 10
Strong MOAT
Composite Rating
A
Overall Score
4 / 5
High
DCF Score
5 / 5
High
ROE Score
5 / 5
High
ROA Score
5 / 5
High
D/E Score
3 / 5
Medium
P/E Score
2 / 5
Medium
P/Book Score
2 / 5
Medium
Operational MOAT
✗ Below peers
★ Strong MOAT
-
Revenue growth Medical - Devices: +11.2%+9.8% Q1'26: +10.8% (vs Q1'25)
-
EPS growth Medical - Devices: +28.5%+37.4% ★ Q1'26: +9.3% (vs Q1'25)
-
FCF margin FCF growth · Medical - Devices: +30.9%+30.1% ★ Q1'26: +36.4% (vs Q1'25)
-
EBIT margin Medical - Devices: +6.2%+32.6% ★ Q1'26: +34.9% (vs Q1'25)
-
ROIC Medical - Devices: +3.3%+25.0% ★ Q1'26: +28.0% (vs Q1'25)
-
Share dilution Medical - Devices: 0.0%-0.1% ★ Q1'26: -0.1% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Devices: -0.35×0.45× Q1'26: 0.42× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Jun 2011 actual |
Jun 2012 actual |
Jun 2013 actual |
Jun 2014 actual |
Jun 2015 actual |
Jun 2016 actual |
Jun 2017 actual |
Jun 2018 actual |
Jun 2019 actual |
Jun 2020 actual |
Jun 2021 actual |
Jun 2022 actual |
Jun 2023 actual |
Jun 2024 actual |
Jun 2025 actual |
Jun 2026 20 Rev. Ana. 13 EPS Ana. |
Jun 2027 20 Rev. Ana. 13 EPS Ana. |
Jun 2028 24 Rev. Ana. 10 EPS Ana. |
Jun 2029 22 Rev. Ana. 4 EPS Ana. |
Jun 2030 14 Rev. Ana. 4 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
1.24B
est: 1.05B (+18.1%)
|
1.37B
est: 1.23B (+11.2%)
|
1.51B
est: 1.31B (+15.6%)
|
1.55B
est: 1.52B (+2.3%)
|
1.68B
est: 1.66B (+0.9%)
|
1.84B
est: 1.83B (+0.7%)
|
2.07B
est: 2.07B (-0.2%)
|
2.34B
est: 2.34B (-0.2%)
|
2.61B
est: 2.60B (+0.1%)
|
2.96B
est: 2.94B (+0.4%)
|
3.20B
est: 3.12B (+2.5%)
|
3.58B
est: 3.58B (+0.0%)
|
4.22B
est: 4.24B (-0.4%)
|
4.69B
est: 4.68B (+0.1%)
|
5.15B
est: 5.13B (+0.4%)
|
5.65B
5.64B – 5.66B
+10.2% YoY
|
6.08B
5.99B – 6.11B
+7.6% YoY
|
6.50B
6.49B – 6.50B
+6.9% YoY
|
7.00B
6.92B – 7.06B
+7.7% YoY
|
7.70B
7.61B – 7.77B
+10.0% YoY
|
| EBITDA |
374.32M
est: 322.62M (+16.0%)
|
422.59M
est: 278.13M (+51.9%)
|
469.79M
est: 371.01M (+26.6%)
|
484.87M
est: 477.78M (+1.5%)
|
482.29M
est: 502.18M (-4.0%)
|
522.72M
est: 499.37M (+4.7%)
|
568.89M
est: 516.45M (+10.2%)
|
680.22M
est: 556.27M (+22.3%)
|
705.80M
est: 679.94M (+3.8%)
|
990.43M
est: 714.46M (+38.6%)
|
1.10B
est: 840.91M (+31.3%)
|
1.18B
est: 1.10B (+6.8%)
|
1.36B
est: 1.22B (+11.3%)
|
1.53B
est: 1.86B (-17.4%)
|
1.91B
est: 2.03B (-5.9%)
|
2.24B
2.24B – 2.24B
+10.2% YoY
|
2.41B
2.37B – 2.42B
+7.6% YoY
|
2.58B
2.58B – 2.58B
+6.9% YoY
|
2.77B
2.74B – 2.80B
+7.7% YoY
|
3.05B
3.02B – 3.08B
+10.0% YoY
|
| EBIT |
305.47M
est: 238.91M (+27.9%)
|
336.73M
est: 242.61M (+38.8%)
|
391.51M
est: 306.10M (+27.9%)
|
411.41M
est: 379.53M (+8.4%)
|
409.24M
est: 399.47M (+2.4%)
|
435.87M
est: 405.18M (+7.6%)
|
456.73M
est: 412.78M (+10.6%)
|
560.26M
est: 448.75M (+24.8%)
|
555.00M
est: 561.32M (-1.1%)
|
809.06M
est: 589.64M (+37.2%)
|
912.35M
est: 702.99M (+29.8%)
|
982.80M
est: 930.37M (+5.6%)
|
1.16B
est: 789.92M (+47.1%)
|
1.31B
est: 1.72B (-23.7%)
|
1.68B
est: 1.88B (-10.9%)
|
2.07B
2.07B – 2.08B
+10.2% YoY
|
2.23B
2.20B – 2.24B
+7.6% YoY
|
2.39B
2.38B – 2.39B
+6.9% YoY
|
2.57B
2.54B – 2.59B
+7.7% YoY
|
2.83B
2.79B – 2.85B
+10.0% YoY
|
| Net Income |
226.99M
est: 194.86M (+16.5%)
|
254.85M
est: 210.41M (+21.1%)
|
307.13M
est: 262.60M (+17.0%)
|
345.27M
est: 321.30M (+7.5%)
|
352.89M
est: 345.87M (+2.0%)
|
352.41M
est: 343.96M (+2.5%)
|
342.28M
est: 333.43M (+2.7%)
|
315.59M
est: 279.69M (+12.8%)
|
404.59M
est: 432.01M (-6.3%)
|
621.67M
est: 411.03M (+51.2%)
|
474.51M
est: 559.05M (-15.1%)
|
779.44M
est: 492.41M (+58.3%)
|
897.56M
est: 906.50M (-1.0%)
|
1.02B
est: 1.14B (-10.1%)
|
1.40B
est: 1.39B (+0.8%)
|
1.64B
1.63B – 1.64B
+17.7% YoY
|
1.79B
1.75B – 1.82B
+9.1% YoY
|
1.87B
1.81B – 2.05B
+4.5% YoY
|
2.13B
2.10B – 2.15B
+14.0% YoY
|
2.38B
2.34B – 2.41B
+11.8% YoY
|
| SGA |
371.25M
est: 311.76M (+19.1%)
|
401.62M
est: 366.15M (+9.7%)
|
430.80M
est: 372.81M (+15.6%)
|
450.41M
est: 431.66M (+4.3%)
|
472.63M
est: 462.12M (+2.3%)
|
488.06M
est: 467.21M (+4.5%)
|
553.97M
est: 524.96M (+5.5%)
|
600.37M
est: 534.70M (+12.3%)
|
645.01M
est: 589.17M (+9.5%)
|
676.69M
est: 621.94M (+8.8%)
|
670.39M
est: 532.86M (+25.8%)
|
739.37M
est: 672.31M (+10.0%)
|
874.00M
est: 578.99M (+51.0%)
|
917.14M
est: 946.81M (-3.1%)
|
991.02M
est: 1.04B (-4.5%)
|
1.14B
1.14B – 1.15B
+10.2% YoY
|
1.23B
1.21B – 1.24B
+7.6% YoY
|
1.31B
1.31B – 1.32B
+6.9% YoY
|
1.42B
1.40B – 1.43B
+7.7% YoY
|
1.56B
1.54B – 1.57B
+10.0% YoY
|
| EPS |
1.49
est: 1.16 (+28.4%)
|
1.75
est: 1.35 (+29.6%)
|
2.15
est: 1.69 (+27.2%)
|
2.44
est: 2.34 (+4.3%)
|
2.51
est: 2.39 (+5.2%)
|
2.51
est: 2.65 (-5.4%)
|
2.42
est: 2.79 (-13.2%)
|
2.21
est: 3.49 (-36.6%)
|
2.83
est: 3.61 (-21.5%)
|
4.31
est: 4.51 (-4.4%)
|
3.27
est: 5.30 (-38.2%)
|
5.34
est: 5.71 (-6.5%)
|
6.12
est: 6.50 (-5.9%)
|
6.94
est: 7.73 (-10.2%)
|
9.55
est: 9.51 (+0.4%)
|
11.11
11.08 – 11.13
+16.8% YoY
|
12.24
11.86 – 12.37
+10.2% YoY
|
13.43
12.29 – 13.89
+9.7% YoY
|
14.44
14.23 – 14.62
+7.6% YoY
|
16.15
15.91 – 16.34
+11.8% YoY
|
Recent Grade Changes (3M)
| Date | Firm | Previous | New Grade | Action |
|---|---|---|---|---|
| 2026-05-01 | RBC Capital | Outperform | Outperform | Maintain |
| 2026-04-27 | Keybanc | Overweight | Overweight | Maintain |
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-11 | A | 4/5 | 5/5 | 5/5 | 5/5 | 3/5 | 2/5 | 2/5 |
| 2026-05-08 | A | 4/5 | 5/5 | 5/5 | 5/5 | 3/5 | 3/5 | 2/5 |
| 2026-05-07 | A | 4/5 | 5/5 | 5/5 | 5/5 | 3/5 | 3/5 | 2/5 |
| 2026-05-06 | A | 4/5 | 5/5 | 5/5 | 5/5 | 3/5 | 3/5 | 2/5 |
| 2026-05-05 | A | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 3/5 | 2/5 |
| 2026-05-04 | A | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 3/5 | 2/5 |
| 2026-05-01 | B+ | 3/5 | 5/5 | 5/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-30 | B+ | 3/5 | 5/5 | 5/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-29 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 3/5 | 1/5 |
| 2026-04-28 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 3/5 | 1/5 |
| 2026-04-27 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 3/5 | 1/5 |
| 2026-04-24 | A | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 3/5 | 2/5 |
| 2026-04-23 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-04-22 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-04-21 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-04-20 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-04-17 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-04-16 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-04-15 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 2/5 | 2/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
1.84B
OE per share TTM
12.49
Owner's Yield
6.31%
Maintenance CapEx ratio
2.83%
Maint CapEx / Avg PPE
16.0%
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
296
Total invested
1.40B
Insider transactions (90d)
0
Beneficial owners (>5%)
18
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | The Vanguard Group - 23-1945930 | 16.12M | 11.06% | — | 751.2K | 15.01M | 1.11M | IA | Pennsylvania For | 2022-02-10 | ↗ |
| 2 | (1) BlackRock, Inc. | 13.56M | 9.30% | 11.99M | — | 13.56M | — | HC | Delaware | 2022-02-01 | ↗ |
| 3 | WCM Investment Management, LLC | 9.05M | 6.21% | 9.05M | — | 9.05M | — | IA | Delaware | 2022-02-10 | ↗ |
| 4 | Abigail P. Johnson | 8.26M | 5.82% | — | — | 8.26M | — | IN | United States of America | 2018-02-13 | ↗ |
| 5 | Edward C. Johnson 3d | 5.87M | 7.71% | — | — | 5.87M | — | IN | United States of America | 2007-02-14 | ↗ |
| 6 | FMR Corp. | 5.87M | 7.71% | 342.5K | — | 5.87M | — | HC | Delaware | 2007-02-14 | ↗ |
| 7 | 36-2214610 | 4.64M | 6.11% | 4.64M | — | 4.64M | — | BD, IA | Chicago, Illinois 60606 | 2007-01-17 | ↗ |
| 8 | Colonial First State Investment Group Limited | 2.79M | 8.47% | — | — | — | — | CO | Australia | 2003-02-07 | ↗ |
| 9 | WESTPAC BANKING CORPORATION | 2.21M | 6.92% | — | — | — | 2.21M | BK, HC | AUSTRALIA | 2003-01-08 | ↗ |
| 10 | WESTPAC EQUITY HOLDINGS PTY LIMITED | 2.21M | 6.92% | — | — | — | 2.21M | HC | AUSTRALIA | 2003-01-08 | ↗ |
| 11 | WESTPAC FINANCIAL SERVICES GROUP LIMITED | 2.21M | 6.92% | — | — | — | 2.21M | HC | AUSTRALIA | 2003-01-08 | ↗ |
| 12 | 52-0556948 | 1.74M | 2.20% | 480.9K | — | 1.74M | — | IA | MARYLAND | 2009-02-13 | ↗ |
| 13 | Commonwealth Bank of Australia | 1.57M | 4.93% | — | — | — | 1.57M | CO | Australia | 2003-07-07 | ↗ |
| 14 | ResMed Inc. | 1.50M | 5.38% | 1.50M | — | 1.50M | — | CO | Delaware | 2023-04-06 | ↗ |
| 15 | BARCLAYS GLOBAL INVESTORS, NA. | 776.6K | 3.69% | — | 12.35M | — | 12.35M | BK | Australian Capital Territory, Commonwealth of Australia | 2013-03-18 | ↗ |
| 16 | Principal Financial Group, Inc. | 20.8K | 0.00% | — | 20.8K | — | 20.8K | HC | Delaware | 2003-02-14 | ↗ |
| 17 | Principal Global Investors, LLC | 20.8K | 0.00% | — | — | — | — | IA | Delaware | 2003-02-14 | ↗ |
| 18 | Jon D. Gruber | — | 0.00% | — | 6.39M | — | 6.39M | IN | Australian Capital Territory, Commonwealth of Australia | 2015-06-10 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
296
-673 vs prev Q
New positions
22
Closed positions
669
Increased
132
Reduced
92
Put/Call ratio
0.00
Calls held
—
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | VANGUARD GROUP INC | 18.88M -158.0K (-0.8%) | 4.55B -663.7M (-12.7%) | 12.89% -0.108 pp | 0.07% -0.012 pp | USD89.76 +168.3% | 84 qtrs — |
| 2 | BLACKROCK, INC. | 12.35M +70.7K (+0.6%) | 2.97B -386.4M (-11.5%) | 8.43% +0.048 pp | 0.05% -0.009 pp | USD243.13 -0.9% | 6 qtrs — |
| 3 | STATE STREET CORP | 6.63M +76.2K (+1.2%) | 1.60B -196.8M (-11.0%) | 4.52% +0.052 pp | 0.05% -0.009 pp | USD93.99 +156.3% | 51 qtrs — |
| 4 | BANK OF NEW YORK MELLON CORP | 4.89M +337.7K (+7.4%) | 1.18B -68.3M (-5.5%) | 3.34% +0.231 pp | 0.21% -0.033 pp | USD168.18 +43.2% | 66 qtrs — |
| 5 | GEODE CAPITAL MANAGEMENT, LLC | 4.30M +51.2K (+1.2%) | 1.03B -126.7M (-10.9%) | 2.94% +0.035 pp | 0.06% -0.010 pp | USD147.72 +63.1% | 78 qtrs — |
| 6 | MORGAN STANLEY | 2.89M +578.6K (+25.0%) | 696.52M +63.3M (+10.0%) | 1.97% +0.395 pp | 0.04% +0.003 pp | USD205.89 +17.0% | 51 qtrs — |
| 7 | INVESCO LTD. | 1.95M -156.8K (-7.4%) | 470.16M -107.1M (-18.5%) | 1.33% -0.107 pp | 0.07% -0.019 pp | USD164.84 +46.1% | 57 qtrs — |
| 8 | NORTHERN TRUST CORP | 1.79M +87.5K (+5.2%) | 430.05M -34.7M (-7.5%) | 1.22% +0.060 pp | 0.05% -0.005 pp | USD120.95 +99.1% | 51 qtrs — |
| 9 | FIRST TRUST ADVISORS LP | 1.52M +1.1M (+240.9%) | 365.54M +243.7M (+200.0%) | 1.04% +0.732 pp | 0.27% +0.175 pp | USD245.85 -2.0% | 10 qtrs — |
| 10 | DEUTSCHE BANK AG\ | 1.41M +787.9K (+126.0%) | 340.46M +169.2M (+98.8%) | 0.97% +0.538 pp | 0.11% +0.054 pp | USD224.92 +7.1% | 50 qtrs — |
| 11 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 1.10M +35.8K (+3.4%) | 265.79M -26.5M (-9.1%) | 0.75% +0.025 pp | 0.04% -0.005 pp | USD136.13 +76.9% | 100 qtrs — |
| 12 | SWEDBANK AB | 1.10M +559.8K (+103.1%) | 265.55M +117.0M (+78.8%) | 0.75% +0.382 pp | 0.26% +0.106 pp | USD236.54 +1.8% | 20 qtrs — |
| 13 | NORDEA INVESTMENT MANAGEMENT AB | 1.08M +294.1K (+37.2%) | 262.03M +44.6M (+20.5%) | 0.74% +0.201 pp | 0.23% +0.035 pp | USD225.54 +6.8% | 53 qtrs — |
| 14 | NORGES BANK | 1.03M +1.0M (+100.0%) | 249.07M +249.1M (+100.0%) | 0.71% +0.706 pp | 0.03% +0.027 pp | USD240.87 +0.0% | 1 qtrs NEW |
| 15 | LEGAL & GENERAL GROUP PLC | 992.5K +34.3K (+3.6%) | 239.07M -23.2M (-8.9%) | 0.68% +0.023 pp | 0.05% -0.006 pp | USD122.07 +97.3% | 53 qtrs — |
| 16 | DIMENSIONAL FUND ADVISORS LP | 980.5K +134.4K (+15.9%) | 236.20M +4.6M (+2.0%) | 0.67% +0.092 pp | 0.05% 0.000 pp | USD154.08 +56.3% | 51 qtrs — |
| 17 | GOLDMAN SACHS GROUP INC | 979.4K +118.6K (+13.8%) | 235.91M +288.5K (+0.1%) | 0.67% +0.081 pp | 0.03% +0.000 pp | USD185.25 +30.0% | 73 qtrs — |
| 18 | UBS GROUP AG | 906.4K +32.9K (+3.8%) | 218.33M -20.8M (-8.7%) | 0.62% +0.023 pp | 0.04% -0.002 pp | USD234.94 +2.5% | 45 qtrs — |
| 19 | UBS ASSET MANAGEMENT AMERICAS INC | 836.4K -70.3K (-7.8%) | 201.47M -46.7M (-18.8%) | 0.57% -0.048 pp | 0.04% -0.011 pp | USD164.22 +46.7% | 90 qtrs — |
| 20 | BANK OF AMERICA CORP /DE/ | 831.0K +7.4K (+0.9%) | 200.17M -25.3M (-11.2%) | 0.57% +0.005 pp | 0.01% -0.001 pp | USD212.56 +13.3% | 52 qtrs — |
| 21 | PRICE T ROWE ASSOCIATES INC /MD/ | 770.4K -1.8K (-0.2%) | 185.57M -25.8M (-12.2%) | 0.53% -0.001 pp | 0.02% -0.003 pp | USD240.81 +0.0% | 75 qtrs — |
| 22 | JPMORGAN CHASE & CO | 585.6K -31.9K (-5.2%) | 141.06M -28.0M (-16.5%) | 0.40% -0.022 pp | 0.01% -0.001 pp | USD209.39 +15.0% | 51 qtrs — |
| 23 | TANDEM INVESTMENT ADVISORS, INC. | 500.1K -5.1K (-1.0%) | 120.47M -17.8M (-12.9%) | 0.34% -0.004 pp | 4.49% -0.235 pp | USD171.56 +40.4% | 37 qtrs — |
| 24 | CAISSE DE DEPOT ET PLACEMENT DU QUEBEC | 480.6K -85.3K (-15.1%) | 115.77M -39.1M (-25.3%) | 0.33% -0.058 pp | 0.20% -0.083 pp | USD243.83 -1.2% | 40 qtrs — |
| 25 | CAPTRUST FINANCIAL ADVISORS | 480.1K -57.6K (-10.7%) | 115.63M -31.5M (-21.4%) | 0.33% -0.039 pp | 0.22% -0.080 pp | USD233.05 +3.4% | 33 qtrs — |
| 26 | PACER ADVISORS, INC. | 479.9K +349.7K (+268.6%) | 115.60M +80.0M (+224.4%) | 0.33% +0.239 pp | 0.30% +0.206 pp | USD242.95 -0.9% | 41 qtrs — |
| 27 | AMUNDI | 474.3K +83.2K (+21.3%) | 114.25M +4.2M (+3.8%) | 0.32% +0.057 pp | 0.03% -0.004 pp | USD222.03 +8.5% | 19 qtrs — |
| 28 | FIL LTD | 448.1K -18.9K (-4.0%) | 107.94M -19.9M (-15.6%) | 0.31% -0.013 pp | 0.08% -0.020 pp | USD201.53 +19.5% | 16 qtrs — |
| 29 | FMR LLC | 415.8K -464.5K (-52.8%) | 100.16M -140.8M (-58.4%) | 0.28% -0.317 pp | 0.01% -0.007 pp | USD232.94 +3.4% | 70 qtrs — |
| 30 | AUSTRALIANSUPER PTY LTD | 408.9K +51.4K (+14.4%) | 98.48M +629.2K (+0.6%) | 0.28% +0.035 pp | 0.46% +0.008 pp | USD235.97 +2.1% | 7 qtrs — |
| 31 | BLACKBARN CAPITAL PARTNERS LP | 400.0K -300.0K (-42.9%) | 96.35M -95.3M (-49.7%) | 0.27% -0.205 pp | 6.34% -7.379 pp | USD273.73 -12.0% | 2 qtrs — |
| 32 | SWISS NATIONAL BANK | 399.6K -23.1K (-5.5%) | 96.26M -19.4M (-16.8%) | 0.27% -0.016 pp | 0.06% -0.010 pp | USD123.75 +94.6% | 51 qtrs — |
| 33 | ALLIANCEBERNSTEIN L.P. | 388.4K +20.5K (+5.6%) | 93.55M -7.2M (-7.1%) | 0.27% +0.014 pp | 0.03% -0.002 pp | USD196.97 +22.3% | 61 qtrs — |
| 34 | SUMITOMO MITSUI TRUST HOLDINGS, INC. | 365.6K -11.5K (-3.1%) | 88.05M -15.2M (-14.7%) | 0.25% -0.008 pp | 0.05% -0.008 pp | USD128.02 +88.2% | 53 qtrs — |
| 35 | BARCLAYS PLC | 359.2K +2.7K (+0.8%) | 86.51M -505.7K (-0.6%) | 0.25% +0.002 pp | 0.02% -0.002 pp | USD211.95 +13.6% | 51 qtrs — |
| 36 | HSBC HOLDINGS PLC | 328.8K +49.3K (+17.6%) | 79.32M +2.8M (+3.7%) | 0.22% +0.034 pp | 0.04% -0.002 pp | USD194.58 +23.8% | 56 qtrs — |
| 37 | WELCH & FORBES LLC | 328.4K -1.5K (-0.4%) | 79.09M -11.2M (-12.4%) | 0.22% -0.001 pp | 0.96% -0.129 pp | USD64.65 +272.6% | 75 qtrs — |
| 38 | BNP PARIBAS ASSET MANAGEMENT HOLDING S.A. | 322.8K +128.9K (+66.5%) | 77.77M +25.1M (+47.7%) | 0.22% +0.088 pp | 0.09% -0.047 pp | USD234.94 +2.5% | 44 qtrs — |
| 39 | RHUMBLINE ADVISERS | 320.2K +1.2K (+0.4%) | 77.12M -10.2M (-11.7%) | 0.22% +0.001 pp | 0.06% -0.008 pp | USD116.39 +107.0% | 52 qtrs — |
| 40 | MITSUBISHI UFJ KOKUSAI ASSET MANAGEMENT CO., LTD. | 309.1K +19.5K (+6.7%) | 75.67M -3.6M (-4.5%) | 0.21% +0.013 pp | 0.05% -0.006 pp | USD204.36 +17.9% | 53 qtrs — |
| 41 | NUVEEN, LLC | 311.3K +2.4K (+0.8%) | 74.99M -9.6M (-11.3%) | 0.21% +0.002 pp | 0.02% -0.003 pp | USD225.35 +6.9% | 4 qtrs — |
| 42 | AMERICAN CAPITAL MANAGEMENT INC | 307.0K -3.9K (-1.3%) | 73.94M -11.2M (-13.1%) | 0.21% -0.003 pp | 3.26% -0.128 pp | USD71.32 +237.7% | 54 qtrs — |
| 43 | RENAISSANCE TECHNOLOGIES LLC | 304.5K +246.5K (+425.0%) | 73.34M +57.5M (+361.9%) | 0.21% +0.168 pp | 0.11% +0.093 pp | USD239.79 +0.5% | 7 qtrs — |
| 44 | ALLIANZ ASSET MANAGEMENT GMBH | 297.8K -59.7K (-16.7%) | 71.72M -26.1M (-26.7%) | 0.20% -0.041 pp | 0.07% -0.037 pp | USD234.90 +2.5% | 51 qtrs — |
| 45 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 289.8K +63.7K (+28.2%) | 69.80M +7.9M (+12.8%) | 0.20% +0.044 pp | 0.01% +0.001 pp | USD224.39 +7.3% | 51 qtrs — |
| 46 | ROYAL BANK OF CANADA | 285.9K -420.5K (-59.5%) | 68.87M -124.5M (-64.4%) | 0.20% -0.287 pp | 0.01% -0.021 pp | USD234.42 +2.8% | 51 qtrs — |
| 47 | BNP PARIBAS ARBITRAGE, SNC | 283.8K +127.1K (+81.1%) | 68.37M +25.5M (+59.4%) | 0.19% +0.087 pp | 0.03% +0.008 pp | USD224.00 +7.5% | 51 qtrs — |
| 48 | CALIFORNIA PUBLIC EMPLOYEES RETIREMENT SYSTEM | 280.6K -6.5K (-2.3%) | 67.58M -11.0M (-14.0%) | 0.19% -0.004 pp | 0.04% -0.008 pp | USD121.81 +97.7% | 58 qtrs — |
| 49 | VICTORY CAPITAL MANAGEMENT INC | 279.9K -80.6K (-22.4%) | 67.43M -31.3M (-31.7%) | 0.19% -0.055 pp | 0.04% -0.020 pp | USD237.32 +1.5% | 43 qtrs — |
| 50 | ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | 273.6K +173.6K (+173.6%) | 65.90M +38.5M (+140.8%) | 0.19% +0.119 pp | 0.04% +0.021 pp | USD252.79 -4.7% | 7 qtrs — |
| 51 | STEPHENS INVESTMENT MANAGEMENT GROUP LLC | 273.4K -11.6K (-4.1%) | 65.85M -12.2M (-15.6%) | 0.19% -0.008 pp | 0.86% -0.154 pp | USD98.80 +143.8% | 73 qtrs — |
| 52 | AMERIPRISE FINANCIAL INC | 268.2K +109.4K (+68.9%) | 64.60M +21.1M (+48.6%) | 0.18% +0.075 pp | 0.01% +0.005 pp | USD212.89 +13.1% | 51 qtrs — |
| 53 | AQR CAPITAL MANAGEMENT LLC | 255.9K +33.8K (+15.2%) | 61.63M +867.1K (+1.4%) | 0.17% +0.023 pp | 0.03% -0.007 pp | USD225.80 +6.7% | 63 qtrs — |
| 54 | CITIGROUP INC | 253.8K +112.1K (+79.1%) | 61.14M +22.4M (+57.6%) | 0.17% +0.077 pp | 0.03% +0.010 pp | USD215.59 +11.7% | 108 qtrs — |
| 55 | ILEX CAPITAL PARTNERS (UK) LLP | 246.0K +153.1K (+164.9%) | 59.26M +33.8M (+133.1%) | 0.17% +0.105 pp | 1.67% +0.861 pp | USD247.34 -2.6% | 3 qtrs — |
| 56 | NATIONAL PENSION SERVICE | 243.5K +2.7K (+1.1%) | 58.66M -7.3M (-11.0%) | 0.17% +0.002 pp | 0.04% -0.008 pp | USD167.93 +43.4% | 37 qtrs — |
| 57 | ABRDN PLC | 239.2K -37.7K (-13.6%) | 57.62M -18.3M (-24.1%) | 0.16% -0.026 pp | 0.09% -0.031 pp | USD186.75 +29.0% | 34 qtrs — |
| 58 | KBC GROUP NV | 237.6K +132.9K (+126.9%) | 57.23M +28.6M (+99.6%) | 0.16% +0.091 pp | 0.13% +0.062 pp | USD247.21 -2.6% | 53 qtrs — |
| 59 | BANK OF MONTREAL /CAN/ | 236.4K +32.9K (+16.2%) | 56.93M +1.2M (+2.2%) | 0.16% +0.022 pp | 0.02% -0.002 pp | USD201.51 +19.5% | 51 qtrs — |
| 60 | GIVERNY CAPITAL INC. | 235.4K -30.0 (0.0%) | 56.70M -7.7M (-12.0%) | 0.16% +0.000 pp | 1.89% -0.292 pp | USD273.73 -12.0% | 2 qtrs — |
| 61 | CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | 228.6K -5.0K (-2.1%) | 55.05M -8.9M (-13.9%) | 0.16% -0.003 pp | 0.06% -0.011 pp | USD81.97 +193.9% | 52 qtrs — |
| 62 | BLI - BANQUE DE LUXEMBOURG INVESTMENTS | 215.5K -34.8K (-13.9%) | 52.39M -15.5M (-22.8%) | 0.15% -0.024 pp | 1.54% -0.441 pp | USD228.47 +5.4% | 5 qtrs — |
| 63 | FRANKLIN RESOURCES INC | 215.3K -52.4K (-19.6%) | 51.87M -21.4M (-29.2%) | 0.15% -0.036 pp | 0.01% -0.006 pp | USD222.02 +8.5% | 35 qtrs — |
| 64 | SCHRODER INVESTMENT MANAGEMENT GROUP | 209.6K +54.4K (+35.1%) | 50.95M +8.9M (+21.1%) | 0.14% +0.037 pp | 0.04% +0.006 pp | USD227.08 +6.1% | 51 qtrs — |
| 65 | DUNDAS PARTNERS LLP | 205.0K +29.8K (+17.0%) | 49.37M +1.4M (+3.0%) | 0.14% +0.020 pp | 3.48% +0.092 pp | USD210.06 +14.7% | 8 qtrs — |
| 66 | VAUGHAN DAVID INVESTMENTS LLC/IL | 204.9K +794.0 (+0.4%) | 49.36M -6.5M (-11.7%) | 0.14% +0.001 pp | 1.07% -0.132 pp | USD177.70 +35.5% | 9 qtrs — |
| 67 | GREAT WEST LIFE ASSURANCE CO /CAN/ | 204.7K +38.3K (+23.0%) | 49.35M +4.3M (+9.5%) | 0.14% +0.026 pp | 0.09% +0.021 pp | USD160.88 +49.7% | 54 qtrs — |
| 68 | AVISO FINANCIAL INC. | 203.0K +1.7K (+0.8%) | 48.91M -6.2M (-11.3%) | 0.14% +0.001 pp | 1.86% -0.382 pp | USD194.87 +23.6% | 7 qtrs — |
| 69 | MAN GROUP PLC | 199.8K +77.7K (+63.6%) | 48.12M +14.7M (+44.0%) | 0.14% +0.053 pp | 0.08% +0.024 pp | USD247.11 -2.5% | 32 qtrs — |
| 70 | BLAIR WILLIAM & CO/IL | 187.9K -35.9K (-16.0%) | 45.26M -16.0M (-26.1%) | 0.13% -0.025 pp | 0.12% -0.042 pp | USD117.53 +104.9% | 51 qtrs — |
| 71 | PRINCIPAL FINANCIAL GROUP INC | 180.3K +3.8K (+2.1%) | 43.42M -4.9M (-10.1%) | 0.12% +0.003 pp | 0.02% -0.002 pp | USD80.09 +200.7% | 81 qtrs — |
| 72 | BELLEVUE GROUP AG | 161.2K -3.6K (-2.2%) | 38.83M -6.3M (-13.9%) | 0.11% -0.003 pp | 0.74% -0.202 pp | USD181.73 +32.5% | 40 qtrs — |
| 73 | CAPITAL IMPACT ADVISORS, LLC | 159.4K +114.3K (+253.8%) | 38.38M +26.1M (+211.3%) | 0.11% +0.078 pp | 3.00% +0.246 pp | USD238.62 +0.9% | 4 qtrs — |
| 74 | AVIVA PLC | 154.8K +60.0K (+63.2%) | 37.29M +11.3M (+43.6%) | 0.11% +0.041 pp | 0.06% +0.016 pp | USD235.33 +2.4% | 38 qtrs — |
| 75 | WELLS FARGO & COMPANY/MN | 151.2K -4.4K (-2.8%) | 36.42M -6.2M (-14.5%) | 0.10% -0.003 pp | 0.01% -0.002 pp | USD129.38 +86.2% | 57 qtrs — |
| 76 | LOS ANGELES CAPITAL MANAGEMENT LLC | 142.6K -242.2K (-62.9%) | 35.97M -69.4M (-65.9%) | 0.10% -0.165 pp | 0.12% -0.235 pp | USD206.22 +16.8% | 11 qtrs — |
| 77 | SKANDINAVISKA ENSKILDA BANKEN AB (PUBL) | 141.2K +55.1K (+64.1%) | 34.00M +10.5M (+44.4%) | 0.10% +0.038 pp | 0.14% +0.042 pp | USD235.80 +2.2% | 41 qtrs — |
| 78 | KEYBANK NATIONAL ASSOCIATION/OH | 139.2K +10.3K (+8.0%) | 33.52M -1.7M (-4.9%) | 0.10% +0.007 pp | 0.12% -0.004 pp | USD253.69 -5.1% | 40 qtrs — |
| 79 | RUSSELL INVESTMENTS GROUP, LTD. | 136.9K +24.1K (+21.4%) | 33.04M +2.2M (+7.1%) | 0.09% +0.017 pp | 0.04% +0.001 pp | USD217.68 +10.7% | 37 qtrs — |
| 80 | MACQUARIE GROUP LTD | 130.3K +29.0K (+28.6%) | 31.40M +3.7M (+13.2%) | 0.09% +0.020 pp | 0.14% +0.105 pp | USD222.41 +8.3% | 51 qtrs — |
| 81 | BAIRD FINANCIAL GROUP, INC. | 130.3K -28.1K (-17.8%) | 31.39M -12.0M (-27.6%) | 0.09% -0.019 pp | 0.05% -0.021 pp | USD197.97 +21.7% | 43 qtrs — |
| 82 | STATE BOARD OF ADMINISTRATION OF FLORIDA RETIREMENT SYSTEM | 129.2K -6.3K (-4.7%) | 31.11M -6.0M (-16.1%) | 0.09% -0.004 pp | 0.06% -0.010 pp | USD69.39 +247.1% | 51 qtrs — |
| 83 | SEI INVESTMENTS CO | 128.6K -21.0K (-14.1%) | 30.98M -10.0M (-24.4%) | 0.09% -0.014 pp | 0.03% -0.014 pp | USD221.03 +9.0% | 45 qtrs — |
| 84 | VOLORIDGE INVESTMENT MANAGEMENT, LLC | 126.7K +119.7K (+1,700.7%) | 30.52M +28.6M (+1,484.6%) | 0.09% +0.082 pp | 0.11% +0.101 pp | USD242.69 -0.7% | 2 qtrs — |
| 85 | MACKENZIE FINANCIAL CORP | 124.6K -35.3K (-22.1%) | 30.23M -13.5M (-30.9%) | 0.09% -0.024 pp | 0.04% -0.017 pp | USD215.37 +11.8% | 28 qtrs — |
| 86 | KLP KAPITALFORVALTNING AS | 123.7K +32.4K (+35.5%) | 29.78M +4.8M (+19.2%) | 0.08% +0.022 pp | 0.12% +0.016 pp | USD232.36 +3.7% | 5 qtrs — |
| 87 | NEW YORK STATE TEACHERS RETIREMENT SYSTEM | 122.8K -1.0K (-0.8%) | 29.58M -4.3M (-12.7%) | 0.08% -0.001 pp | 0.06% -0.009 pp | USD52.51 +358.7% | 51 qtrs — |
| 88 | WASHINGTON TRUST ADVISORS, INC. | 122.6K -1.5K (-1.2%) | 29.52M -4.4M (-13.1%) | 0.08% -0.001 pp | 2.26% -0.328 pp | USD254.14 -5.2% | 17 qtrs — |
| 89 | NORINCHUKIN BANK, THE | 122.3K +3.5K (+3.0%) | 29.46M -3.0M (-9.4%) | 0.08% +0.002 pp | 0.34% -0.093 pp | USD222.22 +8.4% | 34 qtrs — |
| 90 | TRIODOS INVESTMENT MANAGEMENT BV | 120.6K +— (+0.0%) | 29.32M -3.7M (-11.2%) | 0.08% +0.000 pp | 2.12% -0.269 pp | USD190.39 +26.5% | 8 qtrs — |
| 91 | MEDIOLANUM INTERNATIONAL FUNDS LTD | 120.4K +54.3K (+82.0%) | 29.27M +11.3M (+63.3%) | 0.08% +0.037 pp | 0.29% +0.104 pp | USD235.95 +2.1% | 8 qtrs — |
| 92 | QUANTINNO CAPITAL MANAGEMENT LP | 120.0K -197.0 (-0.2%) | 28.90M -4.0M (-12.1%) | 0.08% 0.000 pp | 0.06% -0.032 pp | USD239.56 +0.5% | 11 qtrs — |
| 93 | MILLENNIUM MANAGEMENT LLC | 118.4K +28.6K (+31.9%) | 28.53M +3.9M (+16.0%) | 0.08% +0.020 pp | 0.01% +0.002 pp | USD236.04 +2.0% | 42 qtrs — |
| 94 | — | 118.0K +118.0K (+100.0%) | 28.42M +28.4M (+100.0%) | 0.08% +0.081 pp | 0.56% +0.558 pp | USD240.87 +0.0% | 1 qtrs NEW |
Ownership breakdown by holder
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.00
Bearish
Ratio by volume
0.00
Bearish
Buys
0
Sells
2
Shares acquired
—
Shares disposed
3.0K
Cash buys
—
Cash sales
2.00
Net activity
-3,000
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-04-07 | Farrell Michael J. | Director / Officer | M-Exempt | A | ResMed Common Stock | 4,991 | 146.34 | 730.4K | 471,214 | D | ↗ |
| 2026-04-01 | Sandercock Brett | Officer | S-Sale | D | ResMed Common Stock | 1,000 | 224.31 | 224.3K | 83,495 | D | ↗ |
| 2026-04-01 | FARRELL PETER C | Director | S-Sale | D | ResMed Common Stock | 2,000 | 225.00 | 450.0K | 60,773 | D | ↗ |
| 2026-03-09 | Farrell Michael J. | Director / Officer | M-Exempt | A | ResMed Common Stock | 4,991 | 146.34 | 730.4K | 471,214 | D | ↗ |
| 2026-03-04 | FARRELL PETER C | Director | S-Sale | D | ResMed Common Stock | 2,000 | 260.22 | 520.4K | 62,773 | D | ↗ |
| 2026-03-02 | Sandercock Brett | Officer | S-Sale | D | ResMed Common Stock | 1,000 | 254.30 | 254.3K | 84,495 | D | ↗ |
| 2026-02-09 | Farrell Michael J. | Director / Officer | S-Sale | D | ResMed Common Stock | 4,991 | 273.78 | 1.37M | 466,223 | D | ↗ |
| 2026-02-04 | Rider Michael J | Officer | S-Sale | D | ResMed Common Stock | 50 | 260.00 | 13.0K | 9,691 | D | ↗ |
| 2026-02-04 | FARRELL PETER C | Director | S-Sale | D | ResMed Common Stock | 2,000 | 251.31 | 502.6K | 64,773 | D | ↗ |
| 2026-02-02 | Sandercock Brett | Officer | S-Sale | D | ResMed Common Stock | 1,000 | 257.03 | 257.0K | 85,495 | D | ↗ |
| 2026-01-07 | Farrell Michael J. | Director / Officer | M-Exempt | A | ResMed Common Stock | 4,991 | 146.34 | 730.4K | 471,214 | D | ↗ |
| 2026-01-07 | FARRELL PETER C | Director | S-Sale | D | ResMed Common Stock | 2,000 | 248.83 | 497.7K | 66,773 | D | ↗ |
| 2026-01-02 | Sandercock Brett | Officer | S-Sale | D | ResMed Common Stock | 1,000 | 241.75 | 241.8K | 86,495 | D | ↗ |
| 2026-01-02 | Rider Michael J | Officer | S-Sale | D | ResMed Common Stock | 50 | 241.75 | 12.1K | 9,741 | D | ↗ |
| 2025-12-08 | Farrell Michael J. | Director / Officer | M-Exempt | D | ResMed Common Stock Options | 4,991 | 146.34 | 730.4K | 54,903 | D | ↗ |
| 2025-12-03 | FARRELL PETER C | Director | S-Sale | D | ResMed Common Stock | 2,000 | 251.47 | 502.9K | 68,773 | D | ↗ |
| 2025-12-01 | Sandercock Brett | Officer | S-Sale | D | ResMed Common Stock | 1,000 | 244.16 | 244.2K | 87,495 | D | ↗ |
| 2025-12-01 | Rider Michael J | Officer | S-Sale | D | ResMed Common Stock | 50 | 244.16 | 12.2K | 9,791 | D | ↗ |
| 2025-11-25 | De Witte Jan | Director | S-Sale | D | ReMed Common Stock | 2,055 | 255.00 | 524.0K | 4,261 | D | ↗ |
| 2025-11-24 | Mowad-Nassar Nicole | Director | A-Award | A | ResMed Common Stock Options | 1,331 | 250.52 | 333.4K | 1,331 | D | ↗ |
| 2025-11-24 | Farrell Michael J. | Director / Officer | A-Award | A | ResMed Common Stock Options | 33,288 | 250.52 | 8.34M | 33,288 | D | ↗ |
| 2025-11-24 | FARRELL PETER C | Director | A-Award | A | ResMed Common Stock Options | 1,331 | 250.52 | 333.4K | 1,331 | D | ↗ |
| 2025-11-20 | Tan Desney | Director | A-Award | A | ResMed Common Stock | 1,073 | 0.00 | — | 6,002 | D | ↗ |
| 2025-11-20 | TAYLOR RONALD R | Director | A-Award | A | ResMed Common Stock | 1,073 | 0.00 | — | 24,771 | D | ↗ |
| 2025-11-20 | Sandercock Brett | Officer | A-Award | A | ResMed Common Stock | 2,710 | 0.00 | — | 88,495 | D | ↗ |
| 2025-11-20 | Mowad-Nassar Nicole | Director | A-Award | A | ResMed Common Stock | 536 | 0.00 | — | 777 | D | ↗ |
| 2025-11-20 | Leong Justin | Officer | A-Award | A | ReMed Common Stock | 1,848 | 0.00 | — | 29,028 | D | ↗ |
| 2025-11-20 | Hernandez John | Director | A-Award | A | ResMed Common Stock | 1,073 | 0.00 | — | 5,118 | D | ↗ |
| 2025-11-20 | Gill Harjit | Director | A-Award | A | ResMed Common Stock | 1,073 | 0.00 | — | 10,940 | D | ↗ |
| 2025-11-20 | Farrell Michael J. | Director / Officer | F-InKind | D | ResMed Common Stock | 7,297 | 0.00 | — | 466,223 | D | ↗ |
| 2025-11-20 | FARRELL PETER C | Director | A-Award | A | ResMed Common Stock | 536 | 0.00 | — | 70,773 | D | ↗ |
| 2025-11-20 | Drexler Karen | Director | A-Award | A | ResMed Common Stock | 1,073 | 0.00 | — | 10,602 | D | ↗ |
| 2025-11-20 | DelOrefice Christopher | Director | A-Award | A | ResMed Common Stock | 1,073 | 0.00 | — | 2,423 | D | ↗ |
| 2025-11-20 | De Witte Jan | Director | A-Award | A | ReMed Common Stock | 1,073 | 0.00 | — | 6,316 | D | ↗ |
| 2025-11-20 | Burt Carol | Director | A-Award | A | ResMed Common Stock | 1,073 | 0.00 | — | 2,156 | D | ↗ |
| 2025-11-19 | SULPIZIO RICHARD | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2025-11-14 | FARRELL PETER C | Director | F-InKind | D | ResMed Common Stock | 7,314 | 244.46 | 1.79M | 70,238 | D | ↗ |
| 2025-11-12 | FARRELL PETER C | Director | S-Sale | D | ResMed Common Stock | 2,000 | 252.05 | 504.1K | 66,110 | D | ↗ |
| 2025-11-11 | Rider Michael J | Officer | F-InKind | D | ResMed Common Stock | 715 | 250.10 | 178.9K | 10,342 | D | ↗ |
| 2025-11-11 | Gill Harjit | Director | F-InKind | D | ResMed Common Stock | 38 | 250.10 | 9.6K | 9,867 | D | ↗ |
| 2025-11-11 | Farrell Michael J. | Director / Officer | F-InKind | D | ResMed Common Stock | 2,206 | 250.10 | 551.6K | 459,969 | D | ↗ |
| 2025-11-11 | FARRELL PETER C | Director | F-InKind | D | ResMed Common Stock | 163 | 250.10 | 40.8K | 68,110 | D | ↗ |
| 2025-11-11 | De Witte Jan | Director | S-Sale | D | ReMed Common Stock | 487 | 250.25 | 121.9K | 5,319 | D | ↗ |
| 2025-11-07 | Farrell Michael J. | Director / Officer | S-Sale | D | ResMed Common Stock | 8,011 | 249.75 | 2.00M | 467,866 | D | ↗ |
| 2025-11-03 | Sandercock Brett | Officer | M-Exempt | A | ResMed Common Stock | 2,000 | 101.64 | 203.3K | 88,745 | D | ↗ |
| 2025-10-07 | Farrell Michael J. | Officer | M-Exempt | A | ResMed Common Stock | 8,009 | 101.64 | 814.0K | 475,801 | D | ↗ |
| 2025-10-01 | Sandercock Brett | Officer | M-Exempt | D | ResMed Common Stock Options | 2,000 | 101.64 | 203.3K | 2,000 | D | ↗ |
| 2025-10-01 | Rider Michael J | Officer | S-Sale | D | ResMed Common Stock | 100 | 274.36 | 27.4K | 11,327 | D | ↗ |
| 2025-09-08 | Farrell Michael J. | Officer | M-Exempt | A | ResMed Common Stock | 8,009 | 101.64 | 814.0K | 475,801 | D | ↗ |
| 2025-09-02 | Sandercock Brett | Officer | M-Exempt | A | ResMed Common Stock | 2,000 | 101.64 | 203.3K | 90,745 | D | ↗ |
| 2025-09-02 | Mowad-Nassar Nicole | Director | A-Award | A | ResMed Common Stock | 241 | 0.00 | — | 241 | D | ↗ |
| 2025-08-18 | Hernandez John | Director | M-Exempt | A | ResMed Common Stock | 2,575 | 148.90 | 383.4K | 6,620 | D | ↗ |
| 2025-08-15 | Sandercock Brett | Officer | A-Award | A | ResMed Common Stock | 5,462 | 0.00 | — | 88,745 | D | ↗ |
| 2025-08-15 | Rider Michael J | Officer | A-Award | A | ResMed Common Stock | 2,941 | 0.00 | — | 11,427 | D | ↗ |
| 2025-08-15 | Mowad-Nassar Nicole | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2025-08-15 | Leong Justin | Officer | A-Award | A | ReMed Common Stock | 5,462 | 0.00 | — | 27,180 | D | ↗ |
| 2025-08-15 | Farrell Michael J. | Officer | A-Award | A | ResMed Common Stock | 12,289 | 0.00 | — | 467,792 | D | ↗ |
| 2025-08-07 | Farrell Michael J. | Officer | M-Exempt | A | ResMed Common Stock | 8,009 | 101.64 | 814.0K | 463,512 | D | ↗ |
| 2025-08-05 | Ghoshal Kaushik | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2025-08-01 | Sandercock Brett | Officer | M-Exempt | D | ResMed Common Stock Options | 2,000 | 101.64 | 203.3K | 6,000 | D | ↗ |
| 2025-08-01 | Rider Michael J | Officer | S-Sale | D | ResMed Common Stock | 50 | 281.90 | 14.1K | 8,486 | D | ↗ |
| 2025-07-07 | Farrell Michael J. | Officer | S-Sale | D | ResMed Common Stock | 8,009 | 256.72 | 2.06M | 455,503 | D | ↗ |
| 2025-07-02 | FARRELL PETER C | Director | S-Sale | D | ResMed Common Stock | 945 | 255.49 | 241.4K | 68,273 | D | ↗ |
| 2025-07-01 | Sandercock Brett | Officer | M-Exempt | A | ResMed Common Stock | 917 | 101.64 | 93.2K | 88,166 | D | ↗ |
| 2025-07-01 | Rider Michael J | Officer | S-Sale | D | ResMed Common Stock | 66 | 256.99 | 17.0K | 8,536 | D | ↗ |
| 2025-06-09 | Farrell Michael J. | Officer | M-Exempt | D | ResMed Common Stock Options | 8,009 | 101.64 | 814.0K | 40,047 | D | ↗ |
| 2025-06-04 | FARRELL PETER C | Director | S-Sale | D | ResMed Common Stock | 2,000 | 247.32 | 494.6K | 69,218 | D | ↗ |
| 2025-06-02 | Sandercock Brett | Officer | S-Sale | D | ResMed Common Stock | 1,000 | 243.78 | 243.8K | 85,283 | D | ↗ |
| 2025-06-02 | Rider Michael J | Officer | S-Sale | D | ResMed Common Stock | 41 | 243.78 | 10.0K | 8,870 | D | ↗ |
| 2025-05-22 | Sandercock Brett | Officer | S-Sale | D | ResMed Common Stock | 3,644 | 244.59 | 891.3K | 86,283 | D | ↗ |
| 2025-05-20 | De Witte Jan | Director | S-Sale | D | ReMed Common Stock | 2,000 | 243.47 | 486.9K | 5,806 | D | ↗ |
| 2025-05-07 | Farrell Michael J. | Officer | M-Exempt | A | ResMed Common Stock | 8,009 | 101.64 | 814.0K | 463,512 | D | ↗ |
| 2025-05-07 | FARRELL PETER C | Director | S-Sale | D | ResMed Common Stock | 2,000 | 242.25 | 484.5K | 71,218 | D | ↗ |
| 2025-04-08 | Sandercock Brett | Officer | S-Sale | D | ResMed Common Stock | 1,000 | 215.58 | 215.6K | 89,864 | D | ↗ |
| 2025-04-07 | Farrell Michael J. | Officer | S-Sale | D | ResMed Common Stock | 8,009 | 209.85 | 1.68M | 455,472 | D | ↗ |
| 2025-04-02 | FARRELL PETER C | Director | S-Sale | D | ResMed Common Stock | 2,000 | 219.74 | 439.5K | 73,218 | D | ↗ |
| 2025-04-01 | Rider Michael J | Officer | S-Sale | D | ResMed Common Stock | 64 | 222.86 | 14.3K | 8,846 | D | ↗ |
| 2025-03-10 | Sandercock Brett | Officer | S-Sale | D | ResMed Common Stock | 1,000 | 230.36 | 230.4K | 90,864 | D | ↗ |
| 2025-03-10 | Ghoshal Kaushik | Officer | S-Sale | D | ResMed Common Stock | 9,745 | 239.31 | 2.33M | 9,725 | D | ↗ |
| 2025-03-07 | Farrell Michael J. | Officer | M-Exempt | A | ResMed Common Stock | 8,009 | 101.64 | 814.0K | 463,481 | D | ↗ |
| 2025-03-05 | FARRELL PETER C | Director | S-Sale | D | ResMed Common Stock | 2,000 | 227.71 | 455.4K | 75,218 | D | ↗ |
| 2025-03-03 | Rider Michael J | Officer | S-Sale | D | ResMed Common Stock | 64 | 234.10 | 15.0K | 8,910 | D | ↗ |
| 2025-03-03 | Ghoshal Kaushik | Officer | M-Exempt | D | ResMed Common Stock Options | 3,506 | 146.34 | 513.1K | 3,589 | D | ↗ |
| 2025-02-10 | Sandercock Brett | Officer | S-Sale | D | ResMed Common Stock | 1,000 | 238.98 | 239.0K | 91,864 | D | ↗ |
| 2025-02-07 | Farrell Michael J. | Officer | M-Exempt | A | ResMed Common Stock | 8,009 | 101.64 | 814.0K | 463,481 | D | ↗ |
| 2025-02-05 | FARRELL PETER C | Director | S-Sale | D | ResMed Common Stock | 2,000 | 242.11 | 484.2K | 77,218 | D | ↗ |
| 2025-02-03 | Rider Michael J | Officer | S-Sale | D | ResMed Common Stock | 64 | 242.42 | 15.5K | 8,974 | D | ↗ |
| 2025-01-08 | Sandercock Brett | Officer | S-Sale | D | ResMed Common Stock | 1,000 | 234.04 | 234.0K | 92,864 | D | ↗ |
| 2025-01-02 | Rider Michael J | Officer | S-Sale | D | ResMed Common Stock | 75 | 230.99 | 17.3K | 9,038 | D | ↗ |
| 2025-01-02 | FARRELL PETER C | Director | S-Sale | D | ResMed Common Stock | 2,000 | 230.99 | 462.0K | 79,218 | D | ↗ |
| 2024-12-09 | Sandercock Brett | Officer | S-Sale | D | ResMed Common Stock | 1,000 | 244.23 | 244.2K | 93,864 | D | ↗ |
| 2024-12-04 | FARRELL PETER C | Director | S-Sale | D | ResMed Common Stock | 2,000 | 245.65 | 491.3K | 81,218 | D | ↗ |
| 2024-12-02 | Rider Michael J | Officer | S-Sale | D | ResMed Common Stock | 74 | 248.91 | 18.4K | 9,113 | D | ↗ |
| 2024-11-29 | Rider Michael J | Officer | G-Gift | D | ResMed Common Stock | 173 | 0.00 | — | 9,187 | D | ↗ |
| 2024-11-27 | Farrell Michael J. | Officer | G-Gift | D | ResMed Common Stock | 2,000 | 0.00 | — | 2,090 | I | ↗ |
| 2024-11-25 | Farrell Michael J. | Officer | A-Award | A | ResMed Common Stock Options | 33,036 | 249.56 | 8.24M | 33,036 | D | ↗ |
| 2024-11-25 | FARRELL PETER C | Director | A-Award | A | ResMed Common Stock Options | 1,468 | 249.56 | 366.4K | 1,468 | D | ↗ |
| 2024-11-22 | Leong Justin | Officer | S-Sale | D | ReMed Common Stock | 6,160 | 243.09 | 1.50M | 21,718 | D | ↗ |
| 2024-11-20 | Tan Desney | Director | A-Award | A | ResMed Common Stock | 1,083 | 0.00 | — | 4,929 | D | ↗ |
| 2024-11-20 | TAYLOR RONALD R | Director | A-Award | A | ResMed Common Stock | 1,083 | 0.00 | — | 23,698 | D | ↗ |
| 2024-11-20 | SULPIZIO RICHARD | Director | A-Award | A | ResMed Common Stock | 1,083 | 0.00 | — | 17,796 | D | ↗ |
| 2024-11-20 | Hernandez John | Director | A-Award | A | ResMed Common Stock | 1,083 | 0.00 | — | 4,045 | D | ↗ |
| 2024-11-20 | Gill Harjit | Director | A-Award | A | ResMed Common Stock | 1,083 | 0.00 | — | 9,905 | D | ↗ |
| 2024-11-20 | FARRELL PETER C | Director | A-Award | A | ResMed Common Stock | 542 | 0.00 | — | 83,218 | D | ↗ |
| 2024-11-20 | Drexler Karen | Director | A-Award | A | ResMed Common Stock | 1,083 | 0.00 | — | 9,529 | D | ↗ |
| 2024-11-20 | DelOrefice Christopher | Director | A-Award | A | ResMed Common Stock | 1,083 | 0.00 | — | 1,350 | D | ↗ |
| 2024-11-20 | De Witte Jan | Director | A-Award | A | ReMed Common Stock | 1,083 | 0.00 | — | 7,806 | D | ↗ |
| 2024-11-20 | Burt Carol | Director | A-Award | A | ResMed Common Stock | 1,083 | 0.00 | — | 2,851 | D | ↗ |
| 2024-11-12 | De Witte Jan | Director | S-Sale | D | ReMed Common Stock | 796 | 248.81 | 198.1K | 6,723 | D | ↗ |
| 2024-11-11 | Rider Michael J | Officer | F-InKind | D | ResMed Common Stock | 137 | 252.38 | 34.5K | 9,360 | D | ↗ |
| 2024-11-11 | Gill Harjit | Director | F-InKind | D | ResMed Common Stock | 133 | 252.38 | 33.5K | 8,822 | D | ↗ |
| 2024-11-11 | Ghoshal Kaushik | Officer | F-InKind | D | ResMed Common Stock | 1,418 | 252.38 | 357.9K | 9,725 | D | ↗ |
| 2024-11-11 | Farrell Michael J. | Officer | F-InKind | D | ResMed Common Stock | 3,453 | 252.38 | 871.4K | 455,472 | D | ↗ |
| 2024-11-11 | FARRELL PETER C | Director | F-InKind | D | ResMed Common Stock | 528 | 252.38 | 133.2K | 82,676 | D | ↗ |
| 2024-11-08 | Sandercock Brett | Officer | S-Sale | D | ResMed Common Stock | 1,000 | 249.00 | 249.0K | 94,864 | D | ↗ |
| 2024-11-07 | Farrell Michael J. | Officer | S-Sale | D | ResMed Common Stock | 14,683 | 246.26 | 3.62M | 464,254 | D | ↗ |
| 2024-11-06 | FARRELL PETER C | Director | S-Sale | D | ResMed Common Stock | 2,000 | 248.74 | 497.5K | 83,204 | D | ↗ |
| 2024-11-01 | Rider Michael J | Officer | S-Sale | D | ResMed Common Stock | 69 | 242.00 | 16.7K | 10,443 | D | ↗ |
| 2024-10-30 | Ghoshal Kaushik | Officer | J-Other | D | ResMed Common Stock | 9,628 | 0.00 | — | 12,160 | D | ↗ |
| 2024-10-11 | Ghoshal Kaushik | Officer | S-Sale | D | ResMed Common Stock | 4,260 | 238.48 | 1.02M | 21,788 | D | ↗ |
| 2024-10-08 | Sandercock Brett | Officer | S-Sale | D | ResMed Common Stock | 1,000 | 233.47 | 233.5K | 95,812 | D | ↗ |
| 2024-10-07 | Farrell Michael J. | Officer | M-Exempt | A | ResMed Common Stock | 14,683 | 84.98 | 1.25M | 478,852 | D | ↗ |
| 2024-10-02 | FARRELL PETER C | Director | S-Sale | D | ResMed Common Stock | 2,000 | 237.20 | 474.4K | 85,204 | D | ↗ |
| 2024-09-12 | Ghoshal Kaushik | Officer | M-Exempt | A | ResMed Common Stock | 5,000 | 101.64 | 508.2K | 26,788 | — | ↗ |
| 2024-09-09 | Sandercock Brett | Officer | S-Sale | D | ResMed Common Stock | 1,000 | 246.42 | 246.4K | 96,812 | — | ↗ |
| 2024-09-09 | Farrell Michael J. | Officer | M-Exempt | A | ResMed Common Stock | 14,683 | 84.98 | 1.25M | 478,852 | — | ↗ |
| 2024-09-04 | FARRELL PETER C | Director | S-Sale | D | ResMed Common Stock | 2,000 | 239.90 | 479.8K | 87,204 | — | ↗ |
| 2024-09-03 | DelOrefice Christopher | Director | A-Award | A | ResMed Common Stock | 267 | 0.00 | — | 267 | — | ↗ |
| 2024-08-20 | Rider Michael J | Officer | S-Sale | D | ResMed Common Stock | 882 | 231.00 | 203.7K | 10,512 | — | ↗ |
| 2024-08-15 | Sandercock Brett | Officer | A-Award | A | ResMed Common Stock | 7,915 | 0.00 | — | 96,971 | — | ↗ |
| 2024-08-15 | Rider Michael J | Officer | A-Award | A | ResMed Common Stock | 476 | 0.00 | — | 11,394 | — | ↗ |
| 2024-08-15 | Leong Justin | Officer | A-Award | A | ReMed Common Stock | 8,259 | 0.00 | — | 27,000 | — | ↗ |
| 2024-08-15 | Ghoshal Kaushik | Officer | A-Award | A | ResMed Common Stock | 7,915 | 0.00 | — | 20,947 | — | ↗ |
| 2024-08-15 | Farrell Michael J. | Officer | A-Award | A | ResMed Common Stock | 4,098 | 0.00 | — | 464,169 | — | ↗ |
| 2024-08-15 | DelOrefice Christopher | Director | — | D | ResMed Common Stock | 0 | 0.00 | — | 0 | — | ↗ |
| 2024-08-12 | Ghoshal Kaushik | Officer | M-Exempt | D | ResMed Common Stock Options | 6,877 | 95.80 | 658.8K | 0 | — | ↗ |
| 2024-08-08 | Sandercock Brett | Officer | S-Sale | D | ResMed Common Stock | 1,000 | 212.16 | 212.2K | 89,056 | — | ↗ |
| 2024-08-07 | Farrell Michael J. | Officer | M-Exempt | A | ResMed Common Stock | 14,683 | 84.98 | 1.25M | 455,482 | — | ↗ |
| 2024-08-05 | Leong Justin | Officer | S-Sale | D | ReMed Common Stock | 48,000 | 217.07 | 10.42M | 18,741 | — | ↗ |
| 2024-07-08 | Sandercock Brett | Officer | S-Sale | D | ResMed Common Stock | 1,000 | 194.35 | 194.4K | 90,056 | — | ↗ |
| 2024-07-08 | Farrell Michael J. | Officer | M-Exempt | A | ResMed Common Stock | 14,683 | 84.98 | 1.25M | 455,482 | — | ↗ |
| 2024-06-10 | Sandercock Brett | Officer | S-Sale | D | ResMed Common Stock | 1,000 | 209.81 | 209.8K | 91,056 | — | ↗ |
| 2024-06-07 | Farrell Michael J. | Officer | S-Sale | D | ResMed Common Stock | 14,683 | 211.66 | 3.11M | 440,799 | — | ↗ |
| 2024-06-04 | Rider Michael J | Officer | F-InKind | D | ResMed Common Stock | 267 | 206.33 | 55.1K | 6,444 | — | ↗ |
| 2024-05-24 | Burt Carol | Director | G-Gift | D | ResMed Common Stock | 47 | 0.00 | — | 14,892 | — | ↗ |
| 2024-05-15 | FARRELL PETER C | Director | G-Gift | D | ResMed Common Stock | 68,200 | 0.00 | — | 89,204 | — | ↗ |
| 2024-05-15 | De Witte Jan | Director | S-Sale | D | ReMed Common Stock | 360 | 218.29 | 78.6K | 7,519 | — | ↗ |
| 2024-05-08 | Sandercock Brett | Officer | S-Sale | D | ResMed Common Stock | 13,000 | 211.37 | 2.75M | 92,056 | — | ↗ |
| 2024-05-07 | Farrell Michael J. | Officer | M-Exempt | A | ResMed Common Stock | 13,507 | 84.98 | 1.15M | 455,435 | — | ↗ |
| 2024-04-29 | Drexler Karen | Director | S-Sale | D | ResMed Common Stock | 425 | 214.92 | 91.3K | 8,446 | — | ↗ |
| 2024-04-29 | Burt Carol | Director | G-Gift | D | ResMed Common Stock | 234 | 0.00 | — | 14,939 | — | ↗ |
| 2024-03-04 | Rider Michael J | Officer | S-Sale | D | ResMed Common Stock | 81 | 180.00 | 14.6K | 6,607 | — | ↗ |
| 2024-03-01 | Rider Michael J | Officer | S-Sale | D | ResMed Common Stock | 200 | 173.25 | 34.7K | 6,688 | — | ↗ |
| 2024-02-22 | FARRELL PETER C | Director | S-Sale | D | ResMed Common Stock | 10,935 | 182.66 | 2.00M | 157,404 | — | ↗ |
| 2024-01-02 | Douglas Robert Andrew | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2023-11-27 | Sandercock Brett | Officer | S-Sale | D | ResMed Common Stock | 3,000 | 152.62 | 457.9K | 92,962 | — | ↗ |
| 2023-11-22 | Rider Michael J | Officer | G-Gift | D | ResMed Common Stock | 72 | 0.00 | — | 6,888 | — | ↗ |
| 2023-11-20 | Ghoshal Kaushik | Officer | F-InKind | D | ResMed Common Stock | 367 | 148.94 | 54.7K | 12,908 | — | ↗ |
| 2023-11-20 | Farrell Michael J. | Officer | F-InKind | D | ResMed Common Stock | 2,353 | 148.94 | 350.4K | 440,752 | D | ↗ |
| 2023-11-20 | Douglas Robert Andrew | Officer | F-InKind | D | ResMed Common Stock | 1,375 | 148.94 | 204.8K | 13,849 | — | ↗ |
| 2023-11-16 | Tan Desney | Director | A-Award | A | ResMed Common Stock | 1,768 | 0.00 | — | 3,846 | — | ↗ |
| 2023-11-16 | TAYLOR RONALD R | Director | A-Award | A | ResMed Common Stock | 1,768 | 0.00 | — | 22,615 | — | ↗ |
| 2023-11-16 | SULPIZIO RICHARD | Director | A-Award | A | ResMed Common Stock | 1,768 | 0.00 | — | 16,713 | — | ↗ |
| 2023-11-16 | Hernandez John | Director | A-Award | A | ResMed Common Stock Options | 2,575 | 148.90 | 383.4K | 2,575 | — | ↗ |
| 2023-11-16 | Gill Harjit | Director | A-Award | A | ResMed Common Stock | 1,768 | 0.00 | — | 8,955 | — | ↗ |
| 2023-11-16 | Farrell Michael J. | Officer | M-Exempt | D | ResMed Common Stock Options | 3,462 | 57.76 | 200.0K | 0 | D | ↗ |
| 2023-11-16 | FARRELL PETER C | Director | A-Award | A | ResMed Common Stock | 1,768 | 0.00 | — | 180,939 | — | ↗ |
| 2023-11-16 | Drexler Karen | Director | A-Award | A | ResMed Common Stock | 884 | 0.00 | — | 8,871 | — | ↗ |
| 2023-11-16 | De Witte Jan | Director | A-Award | A | ReMed Common Stock | 1,768 | 0.00 | — | 7,879 | — | ↗ |
| 2023-11-16 | Burt Carol | Director | A-Award | A | ResMed Common Stock | 1,768 | 0.00 | — | 3,846 | — | ↗ |
| 2023-11-16 | BLAISE LUCILE | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2023-11-15 | Farrell Michael J. | Officer | M-Exempt | A | ResMed Common Stock | 5,678 | 57.76 | 328.0K | 446,664 | — | ↗ |
| 2023-11-13 | Rider Michael J | Officer | F-InKind | D | ResMed Common Stock | 93 | 143.60 | 13.4K | 6,960 | — | ↗ |
| 2023-11-13 | Gill Harjit | Director | F-InKind | D | ResMed Common Stock | 79 | 143.60 | 11.4K | 7,187 | — | ↗ |
| 2023-11-13 | Ghoshal Kaushik | Officer | F-InKind | D | ResMed Common Stock | 436 | 143.60 | 62.6K | 13,275 | — | ↗ |
| 2023-11-13 | Farrell Michael J. | Officer | F-InKind | D | ResMed Common Stock | 2,181 | 143.60 | 313.2K | 440,986 | — | ↗ |
| 2023-11-13 | FARRELL PETER C | Director | F-InKind | D | ResMed Common Stock | 325 | 143.60 | 46.7K | 179,171 | — | ↗ |
| 2023-11-13 | Douglas Robert Andrew | Officer | F-InKind | D | ResMed Common Stock | 945 | 143.60 | 135.6K | 15,985 | — | ↗ |
| 2023-11-13 | BLAISE LUCILE | Officer | F-InKind | D | ResMed Common Stock | 135 | 143.60 | 19.4K | 10,305 | — | ↗ |
| 2023-11-01 | Rider Michael J | Officer | S-Sale | D | ResMed Common Stock | 25 | 143.42 | 3.6K | 7,358 | — | ↗ |
| 2023-10-16 | Farrell Michael J. | Officer | S-Sale | D | ResMed Common Stock | 5,675 | 140.70 | 798.5K | 449,360 | — | ↗ |
| 2023-10-02 | Rider Michael J | Officer | S-Sale | D | ResMed Common Stock | 25 | 145.92 | 3.6K | 7,383 | — | ↗ |
| 2023-09-15 | Farrell Michael J. | Officer | M-Exempt | A | ResMed Common Stock | 5,675 | 57.76 | 327.8K | 455,035 | — | ↗ |
| 2023-09-01 | Rider Michael J | Officer | S-Sale | D | ResMed Common Stock | 25 | 161.15 | 4.0K | 7,408 | — | ↗ |
| 2023-08-25 | BLAISE LUCILE | Officer | F-InKind | D | ResMed Common Stock | 380 | 165.67 | 62.9K | 10,355 | — | ↗ |
| 2023-08-17 | Sandercock Brett | Officer | A-Award | A | ResMed Common Stock | 4,972 | 0.00 | — | 95,915 | — | ↗ |
| 2023-08-17 | Rider Michael J | Officer | A-Award | A | ResMed Common Stock | 2,247 | 0.00 | — | 7,433 | — | ↗ |
| 2023-08-17 | Ghoshal Kaushik | Officer | A-Award | A | ResMed Common Stock | 2,486 | 0.00 | — | 14,273 | — | ↗ |
| 2023-08-17 | Farrell Michael J. | Officer | A-Award | A | ResMed Common Stock | 12,430 | 0.00 | — | 449,360 | — | ↗ |
| 2023-08-17 | BLAISE LUCILE | Officer | A-Award | A | ResMed Common Stock | 3,294 | 0.00 | — | 10,735 | — | ↗ |
| 2023-08-15 | Farrell Michael J. | Officer | M-Exempt | D | ResMed Common Stock Options | 5,675 | 57.76 | 327.8K | 20,490 | — | ↗ |
| 2023-08-15 | Douglas Robert Andrew | Officer | S-Sale | D | ResMed Common Stock | 1,500 | 181.01 | 271.5K | 250,526 | — | ↗ |
| 2023-08-01 | Rider Michael J | Officer | S-Sale | D | ResMed Common Stock | 25 | 224.12 | 5.6K | 5,186 | — | ↗ |
| 2023-07-17 | Farrell Michael J. | Officer | M-Exempt | A | ResMed Common Stock | 5,675 | 57.76 | 327.8K | 442,605 | — | ↗ |
| 2023-07-17 | Douglas Robert Andrew | Officer | S-Sale | D | ResMed Common Stock | 1,500 | 222.22 | 333.3K | 252,026 | — | ↗ |
| 2023-07-13 | Ghoshal Kaushik | Officer | S-Sale | D | ResMed Common Stock | 500 | 220.00 | 110.0K | 11,787 | — | ↗ |
| 2023-07-03 | Rider Michael J | Officer | S-Sale | D | ResMed Common Stock | 25 | 217.21 | 5.4K | 5,211 | — | ↗ |
| 2023-07-01 | Rider Michael J | Officer | — | D | ResMed Common Stock | 0 | 0.00 | — | 5,236 | — | ↗ |
| 2023-06-30 | PENDARVIS DAVID | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2023-06-15 | Farrell Michael J. | Officer | M-Exempt | A | ResMed Common Stock | 5,675 | 57.76 | 327.8K | 442,605 | — | ↗ |
Executive team
Top executives
EBIT / Employee
168.1K
Shares Outstanding
145.68M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2016 | Michael Farrell Chief executive officer | 845.0K | — | 5.50M | — | 1.08M | 73.6K | 7.50M | 73.35% | ↗ |
| 2 | 2016 | Rob Douglas President and chief operating officer | 694.6K | — | 1.83M | 1.83M | 682.7K | 164.9K | 5.20M | 70.37% | ↗ |
| 3 | 2016 | Brett Sandercock Chief financial officer | 410.6K | — | 1.71M | — | 302.7K | 43.5K | 2.47M | 69.34% | ↗ |
| 4 | 2016 | Jim Hollingshead President – sleep business | 454.2K | — | 1.15M | 382.5K | 360.2K | 69.8K | 2.41M | 63.38% | ↗ |
| 5 | 2016 | Jim Hollingshead President – Americas | 454.2K | — | 1.15M | 382.5K | 360.2K | 69.8K | 2.41M | 63.38% | ↗ |
| 6 | 2016 | David Pendarvis Chief administrative officer, global general counsel and secretary | 507.6K | — | 1.10M | 367.8K | 374.2K | 58.6K | 2.41M | 61.01% | ↗ |
| 7 | 2016 | David Pendarvis Chief administrative officer, global general counsel and secretary | 507.6K | — | 1.10M | 367.8K | 374.2K | 58.6K | 2.41M | 61.01% | ↗ |
| 8 | 2015 | Michael Farrell Chief executive officer | 800.0K | — | 5.00M | — | 861.4K | 52.2K | 6.71M | 74.48% | ↗ |
| 9 | 2015 | Rob Douglas President and chief operating officer | 669.5K | — | 3.27M | — | 648.8K | 122.0K | 4.71M | 69.42% | ↗ |
| 10 | 2015 | Brett Sandercock Chief financial officer | 395.8K | — | 1.60M | — | 319.6K | 41.7K | 2.36M | 67.88% | ↗ |
| 11 | 2015 | David Pendarvis Chief administrative officer, global general counsel and secretary | 489.3K | — | 1.03M | 343.8K | 395.1K | 53.5K | 2.31M | 59.45% | ↗ |
| 12 | 2015 | Jim Hollingshead President – Americas | 437.8K | — | 1.43M | — | 368.2K | 43.4K | 2.28M | 62.74% | ↗ |
| 13 | 2014 | Michael Farrell Chief executive officer | 787.5K | — | 3.65M | — | 714.8K | 45.4K | 5.19M | 70.20% | ↗ |
| 14 | 2014 | Rob Douglas President and chief operating officer | 664.6K | — | 2.80M | — | 543.0K | 166.4K | 4.18M | 67.12% | ↗ |
| 15 | 2014 | Brett Sandercock Chief financial officer | 494.7K | — | 1.38M | — | 336.8K | 49.8K | 2.26M | 60.97% | ↗ |
| 16 | 2014 | David Pendarvis Chief administrative officer, global general counsel and secretary | 485.7K | — | 880.5K | 281.5K | 330.6K | 41.6K | 2.02M | 57.53% | ↗ |
| 17 | 2014 | Jim Hollingshead President – Americas | 434.6K | — | 1.18M | — | 243.9K | 43.8K | 1.90M | 61.95% | ↗ |
| 18 | 2008 | Peter C. Farrell, Executive Chairman and Former Chief Executive Officer | 557.5K | 40.0K | — | 1.42M | 294.2K | 526.8K | 2.84M | 50.00% | ↗ |
| 19 | 2008 | Kieran Gallahue, President Chief Executive Officer * | 547.5K | — | — | 1.11M | 495.3K | 204.9K | 2.35M | 46.97% | ↗ |
| 20 | 2008 | Keith Serzen, Former Chief Operating Officer – Americas ** | 348.8K | — | — | 511.9K | 177.4K | 47.3K | 1.09M | 47.17% | ↗ |
| 21 | 2008 | Brett Sandercock, Chief Financial Officer | 325.3K | — | — | 463.2K | 160.5K | 31.6K | 980.6K | 47.24% | ↗ |
| 22 | 2008 | David Pendarvis, Sr. VP, General Counsel General Counsel | 347.5K | — | — | 426.7K | 169.3K | 26.9K | 970.4K | 43.97% | ↗ |
| 23 | 2008 | Lasse Beijer, Chief Operating Officer – Europe | 279.9K | 93.1K | — | 230.9K | 173.0K | 82.8K | 859.7K | 26.85% | ↗ |
| 24 | 2008 | Rob Douglas, Chief Operating Officer – Sydney | 280.4K | — | — | 371.8K | 139.1K | 28.2K | 819.5K | 45.37% | ↗ |
| 25 | 2007 | Peter C. Farrell, Executive Chairman and Former Chief Executive Officer | 614.0K | 56.1K | — | 1.15M | 413.6K | 171.5K | 2.41M | 47.89% | ↗ |
| 26 | 2007 | Kieran Gallahue, President Chief Executive Officer * | 400.0K | 33.8K | — | 445.2K | 211.3K | 138.0K | 1.23M | 36.24% | ↗ |
| 27 | 2007 | Keith Serzen, Former Chief Operating Officer – Americas ** | 321.3K | 6.6K | — | 456.8K | 165.1K | 50.8K | 1.00M | 45.65% | ↗ |
| 28 | 2007 | David Pendarvis, Sr. VP, General Counsel General Counsel | 315.0K | 21.7K | — | 305.8K | 135.6K | 48.8K | 827.0K | 36.98% | ↗ |
| 29 | 2007 | Brett Sandercock, Chief Financial Officer | 248.0K | 17.1K | — | 296.6K | 106.8K | 3.2K | 671.7K | 44.15% | ↗ |
| 30 | 2007 | Rob Douglas, Chief Operating Officer – Sydney | — | — | — | — | — | — | — | — | ↗ |
| 31 | 2007 | Lasse Beijer, Chief Operating Officer – Europe | — | — | — | — | — | — | — | — | ↗ |
| 32 | 2006 | Adrian Smith , Chief Financial Officer, Sr. Vice President, Finance and COO, Europe | — | — | — | — | — | 45.2K | 45.2K | 0.00% | ↗ |
| 33 | 2006 | Peter C. Farrell, Chief Executive Officer | — | — | — | — | — | 8.2K | 8.2K | 0.00% | ↗ |
| 34 | 2006 | David Pendarvis, Sr. Vice President, General Counsel and Corporate Secretary | — | — | — | — | — | 7.0K | 7.0K | 0.00% | ↗ |
| 35 | 2006 | Kieran Gallahue, President, ResMed Global | — | — | — | — | — | 2.6K | 2.6K | 0.00% | ↗ |
| 36 | 2005 | Kieran Gallahue , President, ResMed Global | 345.0K | 139.1K | — | 112.0K | — | 876.00 | 484.9K | 23.10% | ↗ |
| 37 | 2005 | Adrian Smith, Chief Financial Officer, Sr. Vice President, Finance and COO, Europe | 250.3K | 162.2K | — | 40.0K | — | 24.1K | 436.6K | 9.16% | ↗ |
| 38 | 2005 | David Pendarvis, Sr. Vice President, General Counsel and Corporate Secretary | 252.5K | 136.8K | — | 40.0K | — | 7.0K | 396.4K | 10.09% | ↗ |
| 39 | 2005 | Keith Serzen , Chief Operating Officer, Americas | 250.0K | 128.3K | — | 72.0K | — | 6.9K | 385.2K | 18.69% | ↗ |
| 40 | 2005 | Adrian Smith , Chief Financial Officer, Sr. Vice President, Finance and COO, Europe | — | — | — | — | — | 24.1K | 24.1K | 0.00% | ↗ |
| 41 | 2005 | David Pendarvis, Sr. Vice President, General Counsel and Corporate Secretary | — | — | — | — | — | 7.0K | 7.0K | 0.00% | ↗ |
| 42 | 2005 | Peter C. Farrell, Chief Executive Officer | — | — | — | — | — | 7.0K | 7.0K | 0.00% | ↗ |
| 43 | 2005 | Kieran Gallahue, President, ResMed Global | — | — | — | — | — | 876.00 | 876.00 | 0.00% | ↗ |
| 44 | 2004 | Kieran Gallahue , President, ResMed Global | 300.0K | 155.7K | — | — | — | 1.0K | 456.8K | 0.00% | ↗ |
| 45 | 2004 | Adrian Smith, Chief Financial Officer, Sr. Vice President, Finance and COO, Europe | 209.9K | 154.9K | — | 20.0K | — | 21.1K | 385.9K | 5.18% | ↗ |
| 46 | 2004 | David Pendarvis, Sr. Vice President, General Counsel and Corporate Secretary | 216.5K | 123.4K | — | 12.0K | — | 6.9K | 346.8K | 3.46% | ↗ |
| 47 | 2004 | Adrian Smith , Chief Financial Officer, Sr. Vice President, Finance and COO, Europe | — | — | — | — | — | 21.1K | 21.1K | 0.00% | ↗ |
| 48 | 2004 | Peter C. Farrell, Chief Executive Officer | — | — | — | — | — | 7.5K | 7.5K | 0.00% | ↗ |
| 49 | 2004 | David Pendarvis, Sr. Vice President, General Counsel and Corporate Secretary | — | — | — | — | — | 6.9K | 6.9K | 0.00% | ↗ |
| 50 | 2004 | Kieran Gallahue, President, ResMed Global | — | — | — | — | — | 1.0K | 1.0K | 0.00% | ↗ |
| 51 | 2003 | Peter C. Farrell, Chief Executive Officer | 392.4K | 244.9K | — | — | — | 8.3K | 645.6K | 0.00% | ↗ |
| 52 | 2003 | David Pendarvis, Sr. Vice President, General Counsel and Corporate Secretary | 166.7K | 151.7K | — | — | — | 140.00 | 318.5K | 0.00% | ↗ |
| 53 | 2003 | Adrian Smith, Chief Financial Officer, Sr. Vice President, Finance and COO, Europe | 161.4K | 98.5K | — | 20.0K | — | 14.8K | 274.7K | 7.28% | ↗ |
| 54 | 2003 | Kieran Gallahue , President, ResMed Global | 137.5K | 29.9K | — | — | — | 454.00 | 167.8K | 0.00% | ↗ |
| 55 | 2003 | Peter C. Farrell President and Chief Executive Officer | — | — | — | — | — | — | — | — | ↗ |
| 56 | 2003 | Curt Kenyon Senior Vice President, Telemedicine and Informatics | — | — | — | — | — | — | — | — | ↗ |
| 57 | 2003 | Christopher G. Roberts Executive Vice President | — | — | — | — | — | — | — | — | ↗ |
| 58 | 2003 | David Pendarvis Vice President, General Counsel and Secretary | — | — | — | — | — | — | — | — | ↗ |
| 59 | 2003 | David Pendarvis Vice President, General Counsel and Secretary Adrian Smith Vice President and Chief Financial Officer | — | — | — | — | — | — | — | — | ↗ |
| 60 | 2002 | Christopher G. Roberts Executive Vice President | — | — | — | — | — | — | — | — | ↗ |
| 61 | 2002 | Peter C. Farrell President and Chief Executive Officer | — | — | — | — | — | — | — | — | ↗ |
| 62 | 2002 | David Pendarvis Vice President, General Counsel and Secretary Adrian Smith Vice President and Chief Financial Officer | — | — | — | — | — | — | — | — | ↗ |
| 63 | 2002 | Curt Kenyon Senior Vice President, Telemedicine and Informatics | — | — | — | — | — | — | — | — | ↗ |
| 64 | 2001 | Curt Kenyon Senior Vice President, Telemedicine and Informatics | — | — | — | — | — | — | — | — | ↗ |
| 65 | 2001 | Christopher G. Roberts Executive Vice President | — | — | — | — | — | — | — | — | ↗ |
| 66 | 2001 | David Pendarvis Vice President, General Counsel and Secretary Adrian Smith Vice President and Chief Financial Officer | — | — | — | — | — | — | — | — | ↗ |
| 67 | 2001 | Peter C. Farrell President and Chief Executive Officer | — | — | — | — | — | — | — | — | ↗ |
CEO compensation breakdown
Proxy statements
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Michael J. Farrell | Chief Executive Officer & Chairman | 3M | male |
| Justin Leong | Chief Product Officer | 1M | male |
| Brett A. Sandercock | Chief Financial Officer | 972.0K | male |
| Michael Rider | Chief Legal Officer & Secretary | 889.1K | male |
| Peter C. Farrell | Founder, Chair Emeritus & Non-Executive Director | 413.2K | — |
| Yvonne-Katrin Pucknat | Chief Marketing Officer | — | female |
| Jim Ellis | Chief Compliance Officer | — | male |
| Sallilyn Schwartz | Chief Investor Relations Officer | — | female |
| Vered Keisar | Chief People Officer | — | female |
| Alastair Robertson | Chief Information Officer | — | male |
ESG Rating
ESG Score History MEDICAL - INSTRUMENTS & SUPPLIES
Benchmark vs Sector
Political Trading Activity (25M)
Senate Trading Activity
| Transaction Date | Disclosed | Senator | State | Owner | Type | Amount | Link |
|---|---|---|---|---|---|---|---|
| 2024-05-03 | 2024-06-14 | Tommy Tuberville | AL | Joint | Sale (Full) | $1,001 - $15,000 | ↗ |
| 2023-10-17 | 2023-11-16 | Tommy Tuberville | AL | Joint | Purchase | $1,001 - $15,000 | ↗ |
| 2023-08-29 | 2023-09-05 | Thomas R. Carper | DE | Spouse | Purchase | $1,001 - $15,000 | ↗ |
| 2023-01-11 | 2023-02-02 | Thomas R. Carper | DE | Spouse | Sale (Full) | $1,001 - $15,000 | ↗ |
| 2022-10-05 | 2022-11-10 | Tommy Tuberville | AL | Joint | Sale (Full) | $1,001 - $15,000 | ↗ |
| 2022-03-30 | 2022-04-08 | Tommy Tuberville | AL | Joint | Purchase | $1,001 - $15,000 | ↗ |
| 2021-10-26 | 2021-11-10 | Tommy Tuberville | AL | Joint | Sale (Full) | $1,001 - $15,000 | ↗ |
| 2020-07-09 | 2020-08-04 | Thomas R. Carper | DE | Spouse | Sale (Partial) | $1,001 - $15,000 | ↗ |
| 2020-04-02 | 2020-05-04 | Thomas R. Carper | DE | Spouse | Sale (Partial) | $1,001 - $15,000 | ↗ |
| 2017-08-31 | 2017-09-06 | Thomas R. Carper | DE | Spouse | Purchase | $1,001 - $15,000 | ↗ |
House Trading Activity
| Transaction Date | Disclosed | Representative | District | Owner | Type | Amount | Link |
|---|---|---|---|---|---|---|---|
| 2025-06-04 | 2025-06-18 | Kelly Louise Morrison | MN03 | — | Sale (Full) | $1,001 - $15,000 | ↗ |
| 2025-04-28 | 2025-05-13 | Kelly Louise Morrison | MN03 | — | Sale (Full) | $1,001 - $15,000 | ↗ |
| 2024-11-15 | 2024-12-06 | Ro Khanna | CA17 | — | Purchase | $1,001 - $15,000 | ↗ |
| 2023-10-31 | 2023-11-08 | Ro Khanna | CA17 | Spouse | Purchase | $1,001 - $15,000 | ↗ |
| 2023-10-10 | 2023-11-08 | Ro Khanna | CA17 | Spouse | Purchase | $1,001 - $15,000 | ↗ |
| 2023-10-02 | 2023-11-08 | Ro Khanna | CA17 | — | Purchase | $1,001 - $15,000 | ↗ |
| 2023-08-29 | 2023-09-06 | Ro Khanna | CA17 | — | Sale | $1,001 - $15,000 | ↗ |
| 2023-06-29 | 2023-07-11 | Ro Khanna | CA17 | Spouse | Sale | $1,001 - $15,000 | ↗ |
| 2023-06-26 | 2023-07-11 | Ro Khanna | CA17 | — | Purchase | $1,001 - $15,000 | ↗ |
| 2023-05-23 | 2023-06-12 | Ro Khanna | CA17 | — | Sale | $1,001 - $15,000 | ↗ |
| 2023-05-19 | 2023-06-12 | Ro Khanna | CA17 | Spouse | Sale | $1,001 - $15,000 | ↗ |
| 2022-05-23 | 2022-06-10 | Ro Khanna | CA17 | Spouse | Purchase | $1,001 - $15,000 | ↗ |
| 2022-05-10 | 2022-06-10 | Ro Khanna | CA17 | — | Purchase | $1,001 - $15,000 | ↗ |
| 2022-05-05 | 2022-06-10 | Ro Khanna | CA17 | Spouse | Purchase | $1,001 - $15,000 | ↗ |
| 2022-02-17 | 2022-03-08 | Ro Khanna | CA17 | Spouse | Sale | $1,001 - $15,000 | ↗ |
| 2022-02-14 | 2022-03-08 | Ro Khanna | CA17 | — | Sale | $1,001 - $15,000 | ↗ |
| 2022-01-21 | 2022-02-08 | Ro Khanna | CA17 | Spouse | Purchase | $1,001 - $15,000 | ↗ |
| 2022-01-20 | 2022-02-08 | Ro Khanna | CA17 | — | Purchase | $1,001 - $15,000 | ↗ |
| 2021-02-16 | 2021-03-16 | Peter Meijer | MI03 | — | Sale (Full) | $1,001 - $15,000 | ↗ |
| 2019-02-05 | 2019-02-17 | Bradley S. Schneider | Il10 | Spouse | Sale (Full) | $250,001 - $500,000 | ↗ |
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for RMD
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
